Data retention and archiving in non-interventional studies (NIS) are foundational practices that support the integrity of the scientific process, comply with regulatory requirements, facilitate future research, serve educational purposes, and ensure ethical management of study data. These practices are essential for advancing knowledge, fostering innovation, and ultimately improving health outcomes.
In many jurisdictions, regulatory bodies mandate the retention of research data for a specified period (see below).
Argentina = 2 years
Austria = 15 years
Brazil = 5 years
Germany = 10 years
Japan = 5 years
Netherlands = 15 years
South Korea = 3 years
Turkey = 5 years
Pain Point #1 = Most countries don’t define how long you should retain NIS documents. In these cases, we recommend you defer (refer) to IPSE GPP data retention guidance = At least 5 years after final report or first publication of study results.
Pain Point #2 = Trying to force your non-interventional (observational) study documents into a filing system designed specifically for clinical trials. There is a (reasonably) simple solution for this. Use the real world study document index that was developed from the TMF Reference Model by NIS experts who were keen to mitigate this pain.
CDISC Real World Study Document Index: https://www.cdisc.org/sites/default/files/2023-09/Real_World_Studies_Document_Index_v1_2020_07_29.xlsx
CDISC TMF Reference Model: https://www.cdisc.org/tmf
In conclusion, through adherence to established guidelines and the utilization of resources like the CDISC Real World Study Document Index, researchers can navigate the complexities of data retention, thereby contributing to the broader goals of enhancing knowledge, spurring innovation, and improving global health outcomes.
Share this story...
Real World Evidence (RWE) 201 – China’s Emerging Trend: Embracing Real-World Evidence in Drug Development and Regulation
RWE 201 - China's Emerging Trend: Embracing Real-World Evidence in Drug Development and Regulation - Zhong et al., Advancing the Development of Real-World Data for Healthcare Research in - [...]
Real World Evidence (RWE) 201 – EU – EMA Big Data Steering Group Updates Its Workplan to Accelerate Transformation to Data-Driven Medicines Regulation
RWE 201 - EU - EMA Big Data Steering Group Updates Its Workplan to Accelerate Transformation to Data-Driven Medicines Regulation Updated EMA Big Data Steering Group Workplan: [...]
Real World Evidence (RWE) 201 – Germany’s Draft Health Data Usage Act
RWE 201 - Germany's Draft Health Data Usage Act Draft Health Data Usage Act (GDNG): https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html BfArM Health Research Data Center: https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Forschungsdatenzentrum/_node.html In June 2023, the [...]
RWE 201 | A Landscape Analysis of Regional RWE Frameworks – The European Health Data Space and DARWIN-EU
RWR CONTEXT The European Union (EU) is making significant strides in advancing healthcare through a series of interconnected initiatives. The EU4Health Program aims to bolster health systems, focusing on crisis preparedness and disease [...]
Poland – The Journey towards Real World Evidence and Digital Transformation
RWE 201 - Poland – The Journey towards Real World Evidence and Digital Transformation Real World Evidence (RWE) and Real World Data (RWD) initiatives in Poland are still in [...]
Latvia – Making Early Strides to Implement RWE and RWD Initiatives
RWE 201 - Latvia – Making Early Strides to Implement RWE and RWD Initiatives Latvia is actively working on initiatives to implement Real-World Evidence (RWE) and [...]








